GSDME and Miyoshi myopathy: Doxorubicin (DOX) is widely used as the main pharmaceutical intervention for MM, which is not only usually prescribed in combination with other adjuvant drugs (47–49),but also found to be a inducer of pyroptosis via caspase-3-induced slicing of GSDME (GSDME-N),which could trigger pyroptosis (17, 50).